The Effect of Rosiglitazone on Adipocyte-derived Cytokines in Nondiabetics With the Metabolic Syndrome.

Trial Profile

The Effect of Rosiglitazone on Adipocyte-derived Cytokines in Nondiabetics With the Metabolic Syndrome.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2012

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Metabolic syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Mar 2010 Status changed from active, no longer recruiting to completed.
    • 01 Mar 2010 Results published in Pharmacotherapy.
    • 01 Mar 2010 Primary endpoint 'Adiponectin levels' has been met according to results published in Pharmacotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top